Keeping in mind that many melanoma patients carry a BRAF mutation, and that they develop resistance to BRAF inhibitors, this observation is very interesting as MIF inhibitors could be used to treat many patients in relapse after a treatment with a mutant BRAF inhibitor [23]. The gene discussed is MIF; the disease is melanoma.